Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3–17 years.

Matéria original


REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19


Multi-level inhibition of coronavirus replication by chemical ER stress